Skip to main content

Table 3 Polypharmacy among patients receiving at least one medication other than interferon beta1-b (n = 246)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Number of additional medicationsa Number (%) patientsb
Aged 41–50 years(n = 161) Aged > 50 years(n = 85)
1 46 (28.6 %) 12 (14.1 %)
2–3 63 (39.1 %) 38 (44.7 %)
≥4 52 (32.3 %) 35 (41.2 %)
  1. aAdditional medications defined as drugs other than interferon beta-1b.
  2. b48.2% (161 of 334) aged 41–50 years and 53.8% (85 of 158) aged >50 years were taking additional medications within the safety population (n=492).